Market Intelligence Partners’ Post

𝐒𝐞𝐫𝐮𝐦 𝐆𝐨𝐧𝐚𝐝𝐨𝐭𝐫𝐨𝐩𝐡𝐢𝐧 𝐟𝐨𝐫 𝐈𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 2024-2032: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲:https://lnkd.in/eCRpeBsS The Serum Gonadotrophin for Injection Market is witnessing significant growth driven by the increasing demand for infertility treatments worldwide. As more couples seek to start families later in life, the need for assisted reproductive technologies has risen dramatically. Advancements in gonadotrophin therapy, such as the development of long-acting formulations and the integration of technology into injection devices, have improved patient convenience and adherence. Furthermore, the rising prevalence of male infertility due to factors such as obesity, stress, and environmental pollutants has fueled the demand for gonadotrophin treatments. As healthcare systems prioritize the coverage of infertility treatments and research continues to uncover new applications for gonadotrophins, the market is poised for substantial growth in the coming years. As a Market Research Analyst with over 10 years of experience in the healthcare sector, I am excited to share insights from our latest report on the Serum Gonadotrophin for Injection Market. This report provides both quantitative and qualitative aspects of the market, examining manufacturers, regional analysis, types, and applications. The serum gonadotrophin for injection market is essential for the treatment of infertility, playing a crucial role in assisted reproductive technologies (ART) and non-ART cycles. Valued at approximately USD 1.8 billion in 2023, the market is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 7.4% during this period. Segment-wise growth calculations and forecasts for consumption value are presented for the period 2024-2032, aiding businesses in targeting specific and lucrative market niches for expansion. Serum gonadotrophins, including follicle-stimulating hormone (FSH) and luteinizing hormone (LH), are essential for the regulation of the reproductive system. They stimulate follicular development and ovulation in females and testosterone production in males. The development of highly purified and recombinant gonadotrophin preparations has significantly improved the safety and efficacy of infertility treatments. 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝐒𝐞𝐫𝐮𝐦 𝐆𝐨𝐧𝐚𝐝𝐨𝐭𝐫𝐨𝐩𝐡𝐢𝐧 𝐟𝐨𝐫 𝐈𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧:https://lnkd.in/eCRpeBsS By Type: Recombinant Gonadotrophins, Urinary Gonadotrophins By Application: Female Infertility Treatment, Male Hypogonadism Treatment By Region: Merck KGaA, Darmstadt, Germany, Ferring Pharmaceuticals, Organon, Gedeon Richter Polska, Mitsubishi Tanabe Pharma America, #serumgonadotrophins #infertility #marketresearch #healthcare #cagr #growthforecast #ivf #art #maleinfertility

𝐒𝐞𝐫𝐮𝐦 𝐆𝐨𝐧𝐚𝐝𝐨𝐭𝐫𝐨𝐩𝐡𝐢𝐧 𝐟𝐨𝐫 𝐈𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 2024-2032: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲:https://lnkd.in/eCRpeBsS The Serum Gonadotrophin for Injection Market is witnessing significant growth driven by the increasing demand for infertility treatments worldwide. As more couples seek to start families later in life, the need for assisted reproductive technologies has risen dramatically. Advancements in gonadotrophin therapy, such as the development of long-acting formulations and the integration of technology into injection devices, have improved patient convenience and adherence. Furthermore, the rising prevalence of male infertility due to factors such as obesity, stress, and environmental pollutants has fueled the demand for gonadotrophin treatments. As healthcare systems prioritize the coverage of infertility treatments and research continues to uncover new applications for gonadotrophins, the market is poised for substantial growth in the coming years. As a Market Research Analyst with over 10 years of experience in the healthcare sector, I am excited to share insights from our latest report on the Serum Gonadotrophin for Injection Market. This report provides both quantitative and qualitative aspects of the market, examining manufacturers, regional analysis, types, and applications. The serum gonadotrophin for injection market is essential for the treatment of infertility, playing a crucial role in assisted reproductive technologies (ART) and non-ART cycles. Valued at approximately USD 1.8 billion in 2023, the market is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 7.4% during this period. Segment-wise growth calculations and forecasts for consumption value are presented for the period 2024-2032, aiding businesses in targeting specific and lucrative market niches for expansion. Serum gonadotrophins, including follicle-stimulating hormone (FSH) and luteinizing hormone (LH), are essential for the regulation of the reproductive system. They stimulate follicular development and ovulation in females and testosterone production in males. The development of highly purified and recombinant gonadotrophin preparations has significantly improved the safety and efficacy of infertility treatments. 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝐒𝐞𝐫𝐮𝐦 𝐆𝐨𝐧𝐚𝐝𝐨𝐭𝐫𝐨𝐩𝐡𝐢𝐧 𝐟𝐨𝐫 𝐈𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧:https://lnkd.in/eCRpeBsS By Type: Recombinant Gonadotrophins, Urinary Gonadotrophins By Application: Female Infertility Treatment, Male Hypogonadism Treatment By Region: Merck KGaA, Darmstadt, Germany, Ferring Pharmaceuticals, Organon, Gedeon Richter Polska, Mitsubishi Tanabe Pharma America, #serumgonadotrophins #infertility #marketresearch #healthcare #cagr #growthforecast #ivf #art #maleinfertility

𝐒𝐞𝐫𝐮𝐦 𝐆𝐨𝐧𝐚𝐝𝐨𝐭𝐫𝐨𝐩𝐡𝐢𝐧 𝐟𝐨𝐫 𝐈𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 2024-2032: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲:https://lnkd.in/eCRpeBsS The Serum Gonadotrophin for Injection Market is witnessing significant growth driven by the increasing demand for infertility treatments worldwide. As more couples seek to start families later in life, the need for assisted reproductive technologies has risen dramatically. Advancements in gonadotrophin therapy, such as the development of long-acting formulations and the integration of technology into injection devices, have improved patient convenience and adherence. Furthermore, the rising prevalence of male infertility due to factors such as obesity, stress, and environmental pollutants has fueled the demand for gonadotrophin treatments. As healthcare systems prioritize the coverage of infertility treatments and research continues to uncover new applications for gonadotrophins, the market is poised for substantial growth in the coming years. As a Market Research Analyst with over 10 years of experience in the healthcare sector, I am excited to share insights from our latest report on the Serum Gonadotrophin for Injection Market. This report provides both quantitative and qualitative aspects of the market, examining manufacturers, regional analysis, types, and applications. The serum gonadotrophin for injection market is essential for the treatment of infertility, playing a crucial role in assisted reproductive technologies (ART) and non-ART cycles. Valued at approximately USD 1.8 billion in 2023, the market is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 7.4% during this period. Segment-wise growth calculations and forecasts for consumption value are presented for the period 2024-2032, aiding businesses in targeting specific and lucrative market niches for expansion. Serum gonadotrophins, including follicle-stimulating hormone (FSH) and luteinizing hormone (LH), are essential for the regulation of the reproductive system. They stimulate follicular development and ovulation in females and testosterone production in males. The development of highly purified and recombinant gonadotrophin preparations has significantly improved the safety and efficacy of infertility treatments. 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝐒𝐞𝐫𝐮𝐦 𝐆𝐨𝐧𝐚𝐝𝐨𝐭𝐫𝐨𝐩𝐡𝐢𝐧 𝐟𝐨𝐫 𝐈𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧:https://lnkd.in/eCRpeBsS By Type: Recombinant Gonadotrophins, Urinary Gonadotrophins By Application: Female Infertility Treatment, Male Hypogonadism Treatment By Region: Merck KGaA, Darmstadt, Germany, Ferring Pharmaceuticals, Organon, Gedeon Richter Polska, Mitsubishi Tanabe Pharma America, #serumgonadotrophins #infertility #marketresearch #healthcare #cagr #growthforecast #ivf #art #maleinfertility

𝐒𝐞𝐫𝐮𝐦 𝐆𝐨𝐧𝐚𝐝𝐨𝐭𝐫𝐨𝐩𝐡𝐢𝐧 𝐟𝐨𝐫 𝐈𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 2024-2032: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://lnkd.in/eCRpeBsS The Serum Gonadotrophin for Injection Market is witnessing significant growth driven by the increasing demand for infertility treatments worldwide. As more couples seek to start families later in life, the need for assisted reproductive technologies has risen dramatically. Advancements in gonadotrophin therapy, such as the development of long-acting formulations and the integration of technology into injection devices, have improved patient convenience and adherence. Furthermore, the rising prevalence of male infertility due to factors such as obesity, stress, and environmental pollutants has fueled the demand for gonadotrophin treatments. As healthcare systems prioritize the coverage of infertility treatments and research continues to uncover new applications for gonadotrophins, the market is poised for substantial growth in the coming years. As a Market Research Analyst with over 10 years of experience in the healthcare sector, I am excited to share insights from our latest report on the Serum Gonadotrophin for Injection Market. This report provides both quantitative and qualitative aspects of the market, examining manufacturers, regional analysis, types, and applications. The serum gonadotrophin for injection market is essential for the treatment of infertility, playing a crucial role in assisted reproductive technologies (ART) and non-ART cycles. Valued at approximately USD 1.8 billion in 2023, the market is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 7.4% during this period. Segment-wise growth calculations and forecasts for consumption value are presented for the period 2024-2032, aiding businesses in targeting specific and lucrative market niches for expansion. Serum gonadotrophins, including follicle-stimulating hormone (FSH) and luteinizing hormone (LH), are essential for the regulation of the reproductive system. They stimulate follicular development and ovulation in females and testosterone production in males. The development of highly purified and recombinant gonadotrophin preparations has significantly improved the safety and efficacy of infertility treatments. 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝐒𝐞𝐫𝐮𝐦 𝐆𝐨𝐧𝐚𝐝𝐨𝐭𝐫𝐨𝐩𝐡𝐢𝐧 𝐟𝐨𝐫 𝐈𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧: https://lnkd.in/eCRpeBsS By Type: Recombinant Gonadotrophins, Urinary Gonadotrophins By Application: Female Infertility Treatment, Male Hypogonadism Treatment By Region: Merck KGaA, Darmstadt, Germany, Ferring Pharmaceuticals, Organon, Gedeon Richter Polska, Mitsubishi Tanabe Pharma America, #serumgonadotrophins #infertility #marketresearch #healthcare #cagr #growthforecast #ivf #art #maleinfertility

Researchers are exploring the potential of rapamycin, a drug commonly used to prevent organ transplant rejection, to extend women's fertility by up to five years. Early results from a small pilot study conducted at Columbia University suggest that rapamycin may slow ovarian aging and delay menopause, potentially extending the ovarian reserve, which is the finite number of follicles women are born with. Rapamycin has shown promising results in animal studies, where it increased ovarian reserves and delayed menopause in mice. The current human study involves 50 women aged 35-45, who were randomly assigned to receive either rapamycin or a placebo. Initial findings indicate that rapamycin could decrease ovarian aging by 20%, thus potentially adding about five years to a woman's fertile period. Participants also reported improvements in health, memory, energy levels, and the quality of their skin and hair. The study's promising but preliminary results highlight the need for larger trials to confirm the drug's efficacy and safety. Future research will involve a larger cohort of 1,000 women to provide more definitive evidence. If successful, rapamycin could offer significant benefits to women with low ovarian reserves and those looking to extend their fertility timeline. However, challenges remain, including securing funding for larger studies and determining the optimal dosage to balance benefits with maintaining regular menstrual cycles. The potential to repurpose existing drugs like rapamycin for reproductive health could revolutionize fertility treatments and offer women more control over their reproductive timelines and overall health. https://lnkd.in/gFTpRE9k

The risk of venous thromboembolism in oral contraceptive users: the role of genetic factors—a prospective cohort study of 240,000 women in the UK Biobank - Venous thromboembolism risk according to genetics and oral contraceptive use The HRs for a venous thromboembolism were calculated for both the first 2 years of OC use (shown as blue squares) in the upper part of each group and for the remaining years of OC use (shown as red circles) in the lower part of each comparison group. The HRs for a venous thromboembolism and their error bars, which indicate 95% CIs, are shown in the HR (95% CI) column. The rate per 1000 person-years (RPY) column shows the rate of venous thromboembolism per 1000 person-years that occurred in each group and by the time of occurrence. For the analyses with the PRS, the reference category included individuals in the lowest decile of the PRS (1st PRS) who were not carriers of either FVL or the PTM and who had never used OCs. In the analysis of the risk of FVL and/or PTM, we used nonuser and noncarriers as the control category irrespective of any PRS status. All models were adjusted for body mass index, year of birth, pregnancy and postpartum periods, smoking status, Townsend deprivation index, and the first 4 principal components. https://ow.ly/2rwk50QPnES

PCOS – EARLY CYCLE ANTAGONISM AND MID-CYCLE STIMULATION OF KISSPEPTIN MAY BE THE KEY TO SUCCESSFUL THERAPY https://lnkd.in/eb2k6Wj8 Altered signaling in the neuroendocrine circuits that regulate fertility is the preponderant feature of PCOS. The hypothalamic network of kisspeptin, neurokinin B, and dynorphin A (KNDy) neurons has been identified as the gonadotropin-releasing hormone (GnRH) pulse generator that governs the pattern of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion throughout the ovarian cycle. Patients with PCOS often express high-frequency pulses of LH, increased serum LH, and a high LH-to-FSH ratio. At the level of the ovary, high LH increases androgen synthesis, whereas (relatively) low FSH may contribute to follicular arrest, anovulation.  Moreover, the androgen excess contributes to the impaired negative feedback of ovarian hormones on the LH pulse frequency and thereby fuels an arrhythmic reproductive cycle. In a randomized trial women with PCOS received the NK3R antagonist MLE4901) at doses of either 20 mg/day, 40 mg/day, or 80 mg/day, or placebo for 28 days. Women receiving 80 mg/day of MLE4901 demonstrated a 52% baseline-adjusted reduction in the AUC of LH, a 79% reduction in basal LH secretion, and an LH pulse decrease of 3.6 pulses/8 hours, compared to placebo. Similarly, total testosterone and free testosterone levels were reduced by 29% and 19%, respectively. These effects were marked following 7 days of treatment and continued to be effective until the end of treatment (28 days) in women who did not ovulate during the study.  Another NK3R antagonist, fezolinetant (60 mg daily or 180 mg daily for 12 weeks), reduced the LH:FSH ratio and suppressed hyperandrogenism in women with PCOS. While both doses reduced LH and FSH throughout the study, only fezolinetant 180 mg daily reduced testosterone levels at all time points, thus indicating a dose-dependent response. Overall, fezolinetant 180 mg/day reduced testosterone by 33%, LH by −10.17 IU/L, and FSH by −1.46 IU/L, while fezolinetant 60 mg/day reduced testosterone by 17% nmol/L, LH by −8.21 IU/L, and FSH by −0.92 IU/L (132). No changes were observed in E2 and progesterone levels, endometrial thickness, follicle development, or menstrual cycle irregularity over the 12-week study. The lack of ovulation was probably due to the increased suppressive effects of fezolinetant on NK3R signaling. Kisspeptin has been shown to be requisite for the occurrence of the physiologic ovulatory LH surge. Recently, the kisspeptin receptor agonist MVT-602 was developed through modification of kisspeptin-10 to produce a nonapeptide with increased potency, stability, and water solubility. After single-dose administration of MVT-602, LH concentrations peaked at 24 hours in healthy women, returning to baseline within 48–72 hours. Perhaps the key to treating PCOS is early cycle antagonism and mid-cycle stimulation of kisspeptin.

🔬🌱 Exciting News in Reproductive Medicine! 🌱🔬 I'm thrilled to share the latest findings from our research study investigating the outcomes of ART in women aged 35-40. Our study compared the efficacy of two different protocols: using Recombinant Human Follicle Stimulating Hormone (rhFSH) in combination with Recombinant Human Luteinizing Hormone (rhLH) versus rhFSH alone. Our analysis showed that women of advanced maternal age with normal ovarian response benefit from treatment with combined r-hFSH and r-hLH in a 2:1 ratio versus r-hFSH alone in terms of live birth rate. The effectiveness of treatments is best assessed by RCTs; however, real-world data are valuable for examining the effectiveness of fertility treatment, especially among patient groups that are not well represented in clinical trials. https://lnkd.in/efckvHgD Thomas D'Hooghe Dana Chuderland Brooke Hayward Ro Monica Lispi Dr. Shiv Gupta

Save the date for 2025!!! The program is in preparation ! Facts Views Vis Obgyn. 2024 Apr 11;16(16 Suppl 1):1-32. doi: 10.52054/FVVO.16.s1.011. Many thanks to all friends who participated in Horizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023. Endometriosis is a complex and chronic gynaecological disorder that affects millions of women worldwide, leading to significant morbidity and impacting reproductive health. This condition affects up to 10% of women of reproductive age and is characterised by the presence of endometrial-like tissue outside the uterus, potentially leading to symptoms such as chronic pelvic pain, dysmenorrhoea, dyspareunia, and infertility. The Montreux summit brought a number of experts in this field together to provide a platform for discussion and exchange of ideas. These proceedings summarise the six main topics that were discussed at this summit to shed light on future directions of endometriosis classification, diagnosis, and therapeutical management. The first question addressed the possibility of preventing endometriosis in the future by identifying risk factors, genetic predispositions, and further understanding of the pathophysiology of the condition to develop targeted interventions. The clinical presentation of endometriosis is varied, and the correlation between symptoms severity and disease extent is unclear. While there is currently no universally accepted optimal classification system for endometriosis, several attempts striving towards its optimisation - each with its own advantages and limitations - were discussed. The ideal classification should be able to reconcile disease status based on the various diagnostic tools, and prognosis to guide proper patient tailored management. Regarding diagnosis, we focused on future tools and critically discussed emerging approaches aimed at reducing diagnostic delay. Preserving fertility in endometriosis patients was another debatable aspect of management that was reviewed. Moreover, besides current treatment modalities, potential novel medical therapies that can target underlying mechanisms, provide effective symptom relief, and minimise side effects in endometriotic patients were considered, including hormonal therapies, immunomodulation, and regenerative medicine. Finally, the question of hormonal substitution therapy after radical treatment for endometriosis was debated, weighing the benefits of hormone replacement. Keywords: Endometriosis; prevention; biomarkers; classification; fertility; menopause; artificial intelligence; diagnosis; treatment.

Male Infertility Testing Market 2024-2032: Global Research Report. Request for Sample Copy: https://lnkd.in/d5X5igAQ The Male Infertility Testing Market is poised for significant growth, with a projected compound annual growth rate (CAGR) of 7.5% from 2024 to 2032. Valued at approximately USD 1.2 billion in 2023, this market is anticipated to reach around USD 2.5 billion by 2032. As fertility awareness continues to increase globally, advancements in medical technology and the development of user-friendly, accurate, and cost-effective diagnostic tools are at the forefront of market expansion. Our comprehensive report provides both quantitative and qualitative analysis of the Male Infertility Testing Market. It meticulously examines key market segments, including manufacturers, regional analysis, product types, and applications. This data offers critical insights for stakeholders aiming to gain a competitive advantage. This report aids businesses by offering segment-wise growth calculations and forecasts for consumption value during the 2024-2032 period, helping identify specific and lucrative market niches for business expansion in the Male Infertility Testing Market. To Know Global Scope and Demand of Male Infertility Testing. Request for Sample Copy: https://lnkd.in/d5X5igAQ By Type: Hormonal Tests, Sperm Quality and Count Tests, Genetic and Chromosomal Tests. By Applications: Hospitals, Clinics, Home Diagnostics, Fertility Centers. By Regions: North America, Europe, Asia-Pacific, South America, Middle East & Africa. Key Players: Ferring Pharmaceuticals, Thermo Fisher Scientific, Abbott, Biorad Medisys Pvt Ltd, Siemens Healthineers, Roche Diagnostics India, Neighbouring Markets, Quest Diagnostics, Luminex , Tosoh Bioscience, Inc. BD, Gene Bio-Application Ltd. Vitrolife Group, CooperSurgical, Ortho Clinical Diagnostics, AbbVie, Mayo Clinic, Alpha Laboratories Ltd., Minitube International, Dendreon , NantKwest, Geneticist Inc. The Fertility Partners, Agilent Technologies, Microtest SpA, EndoLab® Mechanical Engineering GmbH, EKF Diagnostics USA (Stanbio Laboratory) , Exosome Diagnostics, a Bio-Techne brand, Anova Fertility & Reproductive Health, Privia Health, Cryolab, Zymo Research Corp, Yokogawa Electric Corporation, Haplogen , CooperSurgical Fertility Solutions, Spermosens AB, Leica Biosystems, BioMedica Diagnostics Inc. #maleinfertilitytesting #fertility #healthcare #diagnostics #medicalresearch #infertility #hormonaltest #spermquality #genetictests #fertilitysolutions #healthcaremarket #medicaltechnology #labdiagnostics #advancedtesting #marketresearch #globalmarket #2024trends #cagr #healthcareinnovation #clinicalstudies #healthcareinsights.